JP5243696B2 - ベンゼン誘導体 - Google Patents

ベンゼン誘導体 Download PDF

Info

Publication number
JP5243696B2
JP5243696B2 JP2006074822A JP2006074822A JP5243696B2 JP 5243696 B2 JP5243696 B2 JP 5243696B2 JP 2006074822 A JP2006074822 A JP 2006074822A JP 2006074822 A JP2006074822 A JP 2006074822A JP 5243696 B2 JP5243696 B2 JP 5243696B2
Authority
JP
Japan
Prior art keywords
group
ethyl
compound
phenoxy
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006074822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007246474A (ja
JP2007246474A5 (enExample
Inventor
修 鶴田
孝 戸澤
直子 安藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority to JP2006074822A priority Critical patent/JP5243696B2/ja
Publication of JP2007246474A publication Critical patent/JP2007246474A/ja
Publication of JP2007246474A5 publication Critical patent/JP2007246474A5/ja
Application granted granted Critical
Publication of JP5243696B2 publication Critical patent/JP5243696B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006074822A 2006-03-17 2006-03-17 ベンゼン誘導体 Expired - Fee Related JP5243696B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006074822A JP5243696B2 (ja) 2006-03-17 2006-03-17 ベンゼン誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006074822A JP5243696B2 (ja) 2006-03-17 2006-03-17 ベンゼン誘導体

Publications (3)

Publication Number Publication Date
JP2007246474A JP2007246474A (ja) 2007-09-27
JP2007246474A5 JP2007246474A5 (enExample) 2009-01-22
JP5243696B2 true JP5243696B2 (ja) 2013-07-24

Family

ID=38591139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006074822A Expired - Fee Related JP5243696B2 (ja) 2006-03-17 2006-03-17 ベンゼン誘導体

Country Status (1)

Country Link
JP (1) JP5243696B2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
FR2917086B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl acrylique activateurs des recepteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
FR2917084B1 (fr) * 2007-06-05 2009-07-17 Galderma Res & Dev Nouveaux derives d'acide 3-phenyl propanoique activateurs des recpteurs de type ppar, leur methode de preparation et leur utilisation dans des compositions cosmetiques ou pharmaceutiques.
CA2692720A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9382188B2 (en) * 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2015163435A1 (ja) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 新規２－アミノ－ピリジン及び２－アミノ－ピリミジン誘導体及びその医薬用途
CN115477588B (zh) * 2022-09-30 2023-11-17 中国药科大学 一种基于胆固醇逆转运途径的调血脂化合物、合成方法及用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
EP1480957A1 (en) * 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
JP2007246474A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
JP5243696B2 (ja) ベンゼン誘導体
JP5225076B2 (ja) チアゾール環を含むカルボン酸誘導体の医薬用途
JP5461398B2 (ja) 含窒素芳香族ヘテロシクリル化合物
CA2672601A1 (en) Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
TW200404060A (en) Fused heterocyclic compounds
JP5587246B2 (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
WO2009076747A1 (en) Viral polymerase inhibitors
WO2016031987A1 (ja) オートタキシン阻害活性を有するピリミジノン誘導体
WO2015000412A1 (zh) 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
JP2022519301A (ja) Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用
JP4939226B2 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
JP2011157349A (ja) 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
MX2015002624A (es) Nuevas tiofenilamidas no anuladas como inhibidores de las proteinas de union a acido graso (fabp) 4 y/o 5.
CN104125960A (zh) 氮杂金刚烷的衍生物及其用途
KR101307066B1 (ko) Ｈｄｌ-콜레스테롤 상승제로서 3-트라이플루오로메틸-피라진-2-카복실산 아미드 유도체
TW200538098A (en) Therapeutic agents
JP2022542613A (ja) ヒトａｔｇｌの阻害剤
JP5815874B2 (ja) Ｈｄｌコレステロール上昇剤としての３−ピリジンカルボン酸ヒドラジド
JP5357894B2 (ja) チアゾール環を含むカルボン酸誘導体およびその医薬用途
TW201404772A (zh) 噁唑烷酮類衍生物、其製備方法及其在醫藥上的應用
CA3223869A1 (en) Compositions for the treatment of hypertension and/or fibrosis
WO2024182736A1 (en) Nbd1 modulators and methods of using the same

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071102

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081202

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100421

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120821

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160412

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees